Anti-Human PDL1x4-1BB antibody

Acasunlimab (GEN1046) 是一种双特异性抗体 (bsAb)，靶向PD-L1和4-1BB。Acasunlimab 通过有条件的4-1BB 刺激增强 T 细胞和 NK 细胞功能，同时构成性地阻断PD-1/PD-L1抑制轴。Acasunlimab 可用于癌症的研究。Acasunlimab (GEN1046), a bispecific antibody (bsAb) designed to target PD-L1 and 4-1BB, functions by enhancing both T-cell and NK-cell response via conditional 4-1BB stimulation and continuously inhibiting the PD-1/PD-L1 axis. This compound is applicable in cancer research.

Acasunlimab (DuoBody-PD-L1×4-1BB) is an investigational, bispecific antibody designed to elicit an antitumor immune response via conditional 4-1BB activation strictly dependent on simultaneous programmed death-ligand 1 (PD-L1) binding. Since 4-1BB is coexpressed with programmed cell death protein-1 (PD-1) on CD8+ T cells, PD-1 blockade and simultaneous costimulation through 4-1BB may synergistically enhance T-cell effector functions. We hypothesized that combining acasunlimab with PD-1 blockade to fully disrupt PD-1 interactions with both PD-L1 and PD-L2 would amplify the depth and duration of antitumor immunity.

Acasunlimab（DuoBody-PD-L1×4-1BB）是一种试验用双特异性抗体，设计用于通过严格依赖于同时程序性死亡配体1（PD-L1）结合的条件性4-1BB活化引发抗肿瘤免疫应答。由于4-1BB与CD 8 + T细胞上的程序性细胞死亡蛋白-I（PD-1）共表达，因此PD-1阻断和通过4-1BB的同时共刺激可以协同增强T细胞效应器功能。我们假设，将acasunlimab与PD-1阻断剂联合使用以完全破坏PD-1与PD-L1和PD-L2的相互作用，将扩大抗肿瘤免疫的深度和持续时间。